To present three new cases of primary intraosseous orbital hemangioma (PIOH), including rare lacrimal bone involvement, and to provide an updated systematic review of previously reported cases. We retrospectively reviewed three patients with orbital PIOH from our institution. Clinical, radiographic, histopathologic, and surgical findings were analyzed. A comprehensive systematic review of 84 previously published PIOH cases was performed to assess demographics, anatomic location, imaging, and treatment outcomes. All three patients had firm, progressively enlarging orbital masses. Imaging showed well-circumscribed, expansile lesions confirmed as PIOH histologically. Case 1 involved the zygomatic and sphenoid bones; Case 2, the maxilla and lacrimal bone; and Case 3, the frontal bone. All underwent orbitotomy with subtotal or complete excision and reconstruction. No recurrence was observed at 1-34 month follow-up. In the systematic review, the zygoma (50%) and frontal bone (44%) were most frequently involved. Common symptoms included swelling, proptosis, pain, and globe displacement. CT was the most used imaging modality. Surgical excision, often with preoperative embolization, remains the preferred treatment. Only one recurrence (1.8%) was reported out of the 56 cases with follow-up data. Orbital PIOH is a rare vascular tumor best managed by tailored surgical excision. Our findings and updated systematic review emphasize individualized planning, particularly in rare sites like the lacrimal bone.
Background: Faricimab is one of the most potent anti-vascular endothelial growth factors used in the management of diabetic macular edema (DME). However, real-world benefits regarding its timing and efficacy are still being explored. Methods: This retrospective non-randomized pilot study aimed to evaluate the efficacy of intravitreal faricimab in the treatment of DME. Eyes initially treatment-naïve for DME with a follow-up of 1 year were grouped as: group 1, where faricimab was introduced within the first six months after the start of treatment; group 2, where it was initiated six or more months after treatment with other drugs. Study parameters included changes in best corrected visual acuity (BCVA) and optical coherence tomography based structural parameters within the 6 × 6 mm optical coherence tomography (OCT) scan regions. Results: Forty-two eyes from 26 patients were analyzed. No statistically significant differences were observed between the groups in cluster-weighted proportions of intra- or sub-retinal fluid, retinal thickness or volume parameters, although group 1 showed modest numerical benefits. SRF showed a trend towards qualitative reduction in group 1, although IRF showed persistence in both groups. Adjusted linear mixed-effects modeling demonstrated no significant impact of early faricimab initiation on functional and anatomical outcomes, which appeared to be influenced by the baseline BCVA, glycemic control, and the number of injections, nullifying the benefits. Conclusions: Faricimab demonstrated modest anatomical improvements with earlier treatment in eyes initially treatment-naïve for DME. Further prospective studies are indicated to assess the treatment strategy and the timing of introduction with faricimab in such eyes.